LEVETIRACETAM- A HELPFUL NEW DRUG
Abstract number :
3.136
Submission category :
Year :
2002
Submission ID :
3507
Source :
www.aesnet.org
Presentation date :
12/7/2002 12:00:00 AM
Published date :
Dec 1, 2002, 06:00 AM
Authors :
Susan M. Lippmann, Georgia D. Montouris, William E. Rosenfeld, Patricia A. Schaefer. Neurology, The comprehensive Epilepsy Care Center for Children and Adults St. Louis, Missouri, St. Louis, MO
RATIONALE: Levetiracetam is a single enantiomer. It is clinically unrelated to existing antiepileptic drugs. Its usage in epilepsy centers and neurology practices is presently being evaluated.
METHODS: 124 patients at our epilepsy center have been started on levetiracetam since August of 1999. Demographic data has been obtained. Seizure freedom and efficacy numbers have been recorded. Levetiracetam serum levels have been obtained.
RESULTS: 109 of the 124 patients (88%) were diagnosed with partial and /or partial with secondary generalized seizures; 15 of the 124 patients (12%) were diagnosed with primary generalized seizures. The patients ranged in age from 12-67 years of age, with 70 females and 54 males. Patients were treated with levetiracetam from 3 to 30 months. 28 of the 124 patients (23%) were seizure free. 15 of the 124 patients (12%) were removed from drug. Full data as to 50% and 75% responder rates and relationships to levels are pending. Dosages of levetiracetam ranged from 500mg to 5500mg/day. Levetiracetam serum levels ranged from 5.6 to 69 ug/ml.
CONCLUSIONS: Levetiracetam has been an easy drug to add on to intractable epilepsy patients. A significant number of patients have become seizure free. Discontinuation rates have been low.
[Supported by: UCB Pharma]; (Disclosure: Grant - UCB Pharma)